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Summary and Key Points 
1. Patients and families (and some health care providers) often think of 
cancer as a single disease. However, cancer is actually many 
diseases; each referred to as a malignancy. 
2. Some malignancies behave indolently and may not require active 
treatment or have an impact on a patient’s life span. 
3. Some malignancies, even when metastatic, may have a long natural 
history and be managed as a chronic disease. 
4. In individual patients, cancers which are normally rapidly fatal may 
have a prolonged natural history. For example, only a few metastases 
may appear, or only one at a time, a phenomenon referred to as 
oligometastatic disease. 
5. Long term management of some malignancies may require 
successive management strategies including a variety of different 
therapies such as hormonal, immune or chemotherapies, surgery or 
radiation to extend survival or palliate symptoms. 
6. Targeted therapies, which exploit specific tumor targets such as 
hormone receptors or cell signaling pathways, have led to extended 
survivals in some cancers and have changed the natural history of 
some biologically aggressive malignancies. 
7. Immune therapies help to interfere with a tumor’s ability to suppress 
the immune system, leading to longer survivals and chronic 
management in some malignancies. 
8. Tumor gene profiling, looking for “driver mutations” that may be 
involved with malignant transformation and proliferation, may increase 
our therapeutic targets and lead to more effective therapies and 
chronic management. 
 
 
Clinical Cases 
Case #1: A 33-year-old female presents with a locally advanced estrogen 
receptor positive HER2/neu-positive breast cancer. She is treated with 
surgery, chemotherapy and radiation. Two years after treatment 
completion she develops progressively severe right arm pain and presents 
with a pathological fracture requiring surgical fixation and radiation. She 
begins treatment with anti-HER2/neu therapy and ovarian suppression. 
Two years later imaging shows progression of bony metastatic disease. 
She is treated with a succession of different anti-HER2-neu based 
therapies with each sign of progression and remains alive with minimal 
bony metastatic disease 10 years after diagnosis working full time and 
caring for her family. 
Case #2: A 70-year-old female, a never smoker, presents with cough and 
weight loss. Chest imaging reveals multiple bilateral pulmonary nodules. 
Biopsy of a lung nodule reveals well-differentiated adenocarcinoma, with 
Epidermal Growth Factor Receptor (EGFR) mutation. Patient is started on 
a tyrosine kinase inhibitor (TKI) targeting the EGFR receptor with 
radiographic resolution of lung disease. She continues on oral targeted 
therapy for three years symptom free until she develops a persistent cough 
with new pulmonary nodules seen on imaging. Patient is treated with six 
cycles of chemotherapy and placed back on a TKI. She remains disease 
free for 17 months and then develops progressive pulmonary disease. She 
is switched to another TKI. At nine months the patient develops brain 
metastases and expires. Time from diagnosis to death–six years. 
Case #3: A 45-year-old male presents with rectal bleeding. Colonoscopy 
reveals a partially fixed mass six cm from the anal verge. Biopsy reveals 
moderately differentiated adenocarcinoma. Staging workup otherwise is 
negative for metastatic disease. Patient is treated with preoperative 
chemotherapy and radiotherapy followed by surgery and six months of 
post-operative chemotherapy. Patient does well for five years until he is 
found to have a new liver lesion. Biopsy of lesion shows adenocarcinoma 
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consistent with a rectal primary. Patient undergoes partial liver resection 
followed by six months of additional chemotherapy. Two years later he is 
found to have a two cm left upper lobe lung nodule. Again biopsy is 
consistent with his rectal primary. Patient undergoes surgical resection of 
his lung lesion and now remains cancer free eight years after his original 
diagnosis. 
Case #4: A 70-year-old man presents with pain in the lumbar spine, five 
years after radical prostatectomy for a Stage II T2cN0M0 Gleason’s 
7(3+4), PSA prior to treatment = 9, adenocarcinoma of the prostate. At this 
time, PSA is 20. MRI demonstrates tumor growing from the vertebral body 
into the canal, compressing the cord at L1. A course of palliative radiation 
therapy relieves his pain, and he remains neurologically intact. He is 
started on Lupron injections for suppression of testosterone and his PSA 
goes down to 2. Six months later, he reports pain in his right shoulder; 
PSA is 10, bone scan is positive in 10 different areas. Again, radiation 
relieves his pain, but then his left hip becomes painful. He is administered 
a dose of Radium-223 and radiation therapy to the left hip. Three years 
later, the right hip hurts. PSA is 30 and bone scan is positive in multiple 
areas. Chemotherapy, right hip radiation and next generation hormonal 
suppression is administered. Four years later he is symptom free, but bone 
scan is positive in new areas and PSA is 59. 
 
 
 
 
 
 
 
 
 
Introduction 
When a patient or family member hears the diagnosis of a cancer, they 
immediately assume that it is an immediate sentence of death. The above 
cases demonstrate that even widely metastatic disease may be managed 
for long term survival with good quality of life. They exemplify a new 
paradigm of treating cancer as a chronic disease, like diabetes or human 
immunodeficiency virus (HIV) infection. 
It is projected that by 2020, there will be 1.9 million new cancer cases per 
year. Of these, approximately 600,000 patients will die of their disease.1 
Many metastatic cancers remain lethal with short median survivals despite 
intensive treatment. However, in contrast to these alarming numbers and 
facts, over the last thirty years survival rates have continued to improve 
from roughly 45% to 65% for all cancers combined.2 This is felt to be due 
to earlier detection and improved therapeutic options.3 Novel treatments 
have prolonged survival in many types of malignancies. Cancers which 
were once fatal are increasingly able to be managed as chronic diseases. 
While most metastatic cancers in adults may not be curable, they often 
can be controlled for long periods of time with a succession of treatments. 
In this chapter, we will examine those cancers with longer natural histories 
and those with extended survivals due to therapeutic advances. 
Important Concepts 
Some malignancies are by nature biologically indolent, having long natural 
histories and requiring minimal intervention over the course of the illness. 
In addition, a variety of different approaches have led to the ability to 
manage some cancers as chronic disease. 
Some cancers may be managed by sequential surgical procedures to 
remove sites of metastases as they arise to extend survival. In other 
malignancies, drugs have been developed that interfere with specific 
targets within cells to interfere with proliferation. The ability to genetically 
sequence tumors to look for mutations that may be used as therapeutic 
targets has made it possible to identify which cancers might be 
successfully treated with such drugs. Finally, the exciting advent of 
immune therapies, which harness the body’s own immune system to fight 
cancer, is showing clinical promise with activity in a variety of different 
malignancies. 
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Biologically Indolent Malignancies 
There are several malignancies that behave indolently and often do not 
impact overall mortality. Some patients may be diagnosed with a cancer 
that is completely asymptomatic for many years and never requires 
therapy. In many cases, there is no evidence that early intervention 
prolongs overall survival. Two examples of these malignancies are chronic 
lymphocytic leukemia (CLL) and prostate cancer. 
Chronic lymphocytic leukemia - CLL is the most common type of leukemia 
(malignant population of white blood cells) in adults. The median age at 
diagnosis is 71 and most patients are asymptomatic at presentation with 
the diagnosis made on routine blood tests revealing lymphocytosis.4 In 
patients diagnosed over the age of 70, this disease often does not impact 
on life expectancy. For symptomatic patients, treatment options include 
cytotoxic chemotherapy, monoclonal antibodies or oral drugs that target 
specific proteins within CLL cells. Treatment is often sequential, utilizing 
each of these modalities at various points in the disease. While the natural 
history of this disease is long with median survival greater than 10 years, 
cure is rare.4 Since therapy is not curative, the goal of any treatment is to 
maintain quality of life in these patients and to minimize side effects of 
therapy. 
Prostate Cancer – The natural history of this malignancy varies 
dramatically from very indolent with prolonged median survival without 
therapy to very aggressive, requiring multiple therapeutic interventions. 
Aggressive prostate cancers occur most commonly in younger men. Many 
men have indolent disease, however, with five year survival in the US of 
99%.2 In addition, a majority of cases are diagnosed in men over the age 
of 70. Older men may have multiple comorbidities, so treatment of an early 
stage prostate cancer may be delayed or avoided.5 Many men remain 
asymptomatic without treatment for many years. 
In men who develop metastatic disease, prostate cancer is generally 
initially exquisitely sensitive to hormone deprivation therapy. Suppressing 
testosterone interrupts proliferation and induces apoptosis of prostate 
cancer cells, leading to disease regression. Patients may be on hormone 
therapy for several years to control disease. In patients who develop 
resistance to hormone therapy, chemotherapy may play a role to control 
disease. Radiation therapy is frequently utilized to palliate symptoms and 
improve the quality of life. According to most recent data, the 5-year 
survival rate for metastatic prostate cancer is about 30%.1 This extended 
survival implies that a substantial number of men with metastatic disease 
will require management of their disease for many years. 
Some cancers which are often aggressive may behave indolently in 
certain patients. For example, both breast cancer and prostate cancer 
sometimes metastasize only to bone. So long as no soft tissue 
metastases are present, patients can live a long time. For these patients, 
one important goal of treatment is relief of symptoms. 
In addition, some cancers will spread to only one or a few spots at a time, 
usually to a single organ, a pattern referred to as oligometastatic disease.3 
Aggressive management of these metastases may offer another chance 
for long term control of the cancer. For example, sarcomas tend to spread 
to lung parenchyma. Resection of a single or a few lung metastases from 
a sarcoma may result in long term control of the disease; sometimes 
patients will benefit from repeated thoracotomies for metastasectomies, or 
repeated ablative procedures. In addition to surgical resection of 
oligometastatic tumors, a variety of other ablative techniques have been 
used to eradicate limited numbers of metastases. Among other 
techniques, these include radio frequency ablation, cryosurgery, and 
stereotactic body radiotherapy. At this time each technique has its own 
unique advantages and risks. To date, there are no comparative data to 
suggest that one technique results in better clinical outcomes than 
another. 
Biologically Aggressive Malignancies with Therapeutic Targets 
Many cancers behave aggressively with potential for widespread 
metastases and short median survival. However, chemotherapy, 
molecular biology, immunology and cytogenetics have improved the 
treatment of certain aggressive malignancies, increasing the median 
survival of some cancers. In many malignancies, one or more exploitable 
targets have been discovered at the molecular level to interfere with clonal 
proliferation of cancer cells. Patients who once would have died within one 
to two years of diagnosis are now living many years. Human epidermal 
growth factor receptor-2 (HER2/neu)-positive breast cancer and 
Philadelphia chromosome-positive chronic myeloid leukemia (CML) are 
two malignancies that exemplify these impressive advances. 
HER2-Positive Breast Cancer – Breast cancer is the most commonly 
diagnosed malignancy in women, aside from skin cancer, and is the 
second leading cause of cancer death in women after lung cancer. 
Approximately 20% of all invasive breast cancers are HER2-positive.6 The 
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protein product of the HER2 gene is a member of the epidermal growth 
factor receptor family. The HER2 gene is amplified in patients with HER2-
positive breast cancer, resulting in an increased number of HER2 
receptors within the membrane of cancer cells. This causes increased 
proliferation of these cells. These cancers are biologically aggressive with 
increased potential for early nodal involvement and distant spread.  
The HER2 receptor became recognized as a potential therapeutic target 
in the late 1980’s leading to the development of multiple agents targeting 
the HER2 receptor. Added to chemotherapeutic regimens, these have 
been shown to increase the disease free and overall survival in patients 
with both localized and metastatic disease.6 Many women with metastatic 
HER2-positive breast cancer can now live for five years or more since the 
advent of these highly effective targeted therapies.7 
Chronic Myeloid Leukemia (CML) – A relatively uncommon hematologic 
malignancy, it is estimated that 9500 new cases will be diagnosed in the 
United States in 2018. The Philadelphia chromosome, the cytogenetic 
definition of CML, is the result of translocation of chromosomes 9 and 22. 
This translocation produces a fusion gene, bcr-abl leading to unregulated 
expression of an activated ABL protein. The activated ABL protein leads 
to proliferation of CML cells. Prior to 2000, the eight year survival rate for 
this disease was less than 20%.8 The tyrosine kinase activity of ABL was 
identified as a therapeutic target in the late 1990’s, leading to drugs that 
would dramatically improve the median survival of this chronic disease.8 
Although these drugs usually do not lead to eradication of the leukemic 
cells, they greatly inhibit clonal proliferation. Studies showed improved 
response rates and overall survivals compared to standard chemotherapy 
alone. The eight-year survival of CML has increased from historic rates of 
20% to almost 90% in recent years.9 
Advent of Immune Therapies 
Recent investigations have led to a better understanding of the interaction 
between cancer cells and the normal immune response. Activated T cells 
normally play a role in fighting infection and cancer surveillance. 
Programmed cell death protein 1 (PD-1) is a protein on the surface of 
activated T cells.10 Many tumor cells express a blocking protein that binds 
to the PD-1 receptor on activated T cells, rendering them inactive and 
unable to attack tumors cells.9 This discovery has led to the development 
of various drugs that suppress the tumor blocking proteins on cancer cells 
that would otherwise suppress the immune response. Several immune-
modulatory drugs have been identified that have shown activity in a 
number of malignancies- lung, melanoma, head and neck cancers to 
name a few. This new class of drugs, referred to as “immune checkpoint 
inhibitors”, appears to have tremendous potential to extend survival of 
many different malignant subtypes.11 
Tumor Gene Profiling 
Intensive research in cancer genomics has led to the ability to entirely 
sequence tumors to look for alterations in genes that may be involved with 
malignant transformation and proliferation. The hope is that exploitable 
targets will be found which will make it possible to target these genetic 
alternations in a therapeutic way. For example, alterations in genes such 
as HER2, braf, egfr, mek, and others can be found with next generation 
sequencing of a variety of cancers. Drugs exist that can target the protein 
products of these various genes.12 For example, osimertinib is a potent 
inhibitor of the tyrosine kinase activity of EGFR and improves outcomes in 
patients with EGFR activated non-small cell lung cancer.13 It is 
conceivable that cancers of different histology that harbor mutations in egfr 
may also respond to a drug like osimertinib. Studies are ongoing that 
assign patients to “targeted” treatment based on gene profiling. The 
discovery of specific genetic abnormalities within individual cancers may 
open up new therapeutic options for patients. Note that this represents a 
fundamental change from thinking of cancer as an organ-based disease. 
In 2017 the FDA approved pembrolizumab for treatment of any metastatic 
cancer that possesses a defect in one of the DNA mismatch repair 
enzymes. This represented the first time a drug had been approved to treat 
cancer on the basis of a molecular defect and not on the basis of the 
cancer cell of origin. It is expected that many more drug approvals will 
follow this same path. Hence, simply identifying a cancer as a “breast” or 
“lung” cancer may not be adequate in the future. It may be necessary to 
identify cancers based on their unique genetic profiles.14 These new 
therapies are often better tolerated than conventional chemotherapy.15 
When modern cancer chemotherapy first appeared in the decades after 
World War II, there was a perception that cancer treatment might follow a 
model like that seen with infections and antibiotics. Perhaps, it was 
thought, with the right chemotherapy drugs, a relatively short course of 
treatment could permanently eradicate cancer in a patient. Unfortunately, 
over the last seventy years that goal has only been achieved in a few adult 
cancers. At this time, a better model for treatment of metastatic adult 
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cancers may be that used in diabetes or, to stay with an infectious disease 
analogy, HIV. Current treatments do not cure either condition. However, 
treatments of diabetes and HIV do an excellent job of controlling disease 
and permitting patients to live for decades. It is hoped that some of the 
newer drugs available to treat cancer will, if not cure, at least permit long 
term control of cancer. 
Conclusion 
Cancer is many diseases, each with its own natural history and expected 
prognosis. But within each cancer, individual cases will behave 
independently. While there are clinical oncology principles that are 
generally applicable to a population of patients with cancer, it is important 
to appreciate that any individual patient may have a cancer that has a 
natural history that is significantly longer than the average for that 
malignancy. For such a patient, the goal of cancer therapy is long term 
control of the disease, with as little toxicity as possible.  
Even when cure is not possible, many patients will experience long term 
survival when cancer is managed as a chronic disease, using any or all of 
the tools in the armamentarium – surgery, radiation therapy, 
chemotherapy, immunotherapy, and nuclear medicine. 
It is important that all physicians be aware of the possibility of achieving 
long term survival with even the most aggressive cancers so that they can 
help patients through the initial shock of a cancer diagnosis to an 
understanding of their situation and so they can manage symptoms in an 
appropriate manner, based on a realistic perception of the patient’s life 
expectancy. 
 
 
Thought Questions 
1. Why do some patients with prostate cancer succumb very quickly 
even with aggressive treatment, while others will survive for years with 
no treatment at all and some will experience years of progression of 
bony metastatic disease? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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2. What characteristics would make a molecule a useful target for cancer 
therapies? What characteristics would preclude use of a molecule as 
a therapy target? 
Your answer: 
 
 
 
 
 
Expert Answer:  
 
 
 
 
3. Why would a cancer which has been controlled by a certain 
chemotherapy regimen or hormonal suppression agent become 
resistant to this regimen, as hormone responsive prostate cancer 
usually will after a while? 
Your answer: 
 
 
 
 
 
Expert Answer:   
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4. Describe mechanisms by which cancer cells may interfere with the 
normal immune response? 
Your answer: 
 
 
 
 
 
 
Expert Answer 
 
 
 
 
 
Glossary 
Ablative procedure – procedure to cause necrosis of tumor deposit, such 
as with stereotactic radiosurgery, freezing or high heat deposition.  
Apoptosis - Genetically determined programmed cell death that occurs as 
a normal part of cell cycle 
HER2/neu - One of the four epidermal growth factor genes involved in 
cellular proliferation 
Metastasectomy - surgical removal of metastases 
Oligometastatic disease- a transitional zone between localized and widely 
metastatic disease 
Ovarian suppression - Blocking ovulation in premenopausal patients 
which may be therapeutic in some cancers, particularly breast cancer 
Targeted therapy – Treatment that is able to exploit some difference 
between cancer cells and normal cells, generally utilizing a unique cellular 
antigen or mutation, to improve effectiveness and decrease toxicity of 
treatment 
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